Novavax’s (NVAX) stock is up after the FDA requested additional data for its COVID-19 vaccine. Unusual at first glance, the phrase “additional data” tends to inspire fear among biotechnology investors ...

Receiving a COVID-19 booster vaccine in the same arm as the first vaccine dose leads to a faster, more effective immune ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

Trinity College Dublin researchers have found that the BNT162b2 COVID-19 vaccine may offer protection beyond its intended ...

In addition, HHS Secretary Robert F. Kennedy Jr addressed the delay in Novavax's approval in a CBS interview earlier this ...

When it comes to getting the most out of a vaccine, arm consistency can make a difference. Some studies suggest that getting ...

Sydney scientists have revealed why receiving a booster vaccine in the same arm as your first dose can generate a more ...

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...

Vaccines have been a central focus for Trump's health leaders, but large-cap players aren't feeling the sting.

Scientists are testing and working on the world’s first acne vaccine, hoping to offer a long-term alternative to current ...

With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: Regeneron Pharmaceuticals ( REGN 0.40%) and Moderna ( MRNA -0.79%).